WINDSOR, Conn., Dec. 1, 2017 /PRNewswire/ -- SCA Pharmaceuticals celebrated the official opening of its 90,000 ft2 manufacturing facility on November 27th, 2017. The private pharmaceutical company specializing in providing high quality sterile admixtures and prefilled syringes to hospitals and surgery centers, is located on Rainbow Road in Windsor, CT.
Governor Dannel P. Malloy and U.S. Senior Senator Richard Blumenthal highlighted a list of important guests on hand to help cut the ribbon.
This new facility "helps us prove the economics of production in Connecticut," stated Gov. Malloy. "I think this is a great investment for the state [and] as they prove their success here, we're hoping other companies will follow suit."
As a leader in 503B industry, SCA partners with hospitals as an extension of their own pharmacy to provide safe medications for patients.
"We are very excited. Our new facility is another milestone in the rapid expansion of our company," stated CEO Milton Boyer. "The Connecticut location allows us to tap into the wealth of pharmaceutical talent in the state as well as position our company strategically to service our east coast clients. We appreciate the tremendous support we have received from the State of Connecticut. They have been an invaluable partner."
Located just north of Hartford, this unique facility will facilitate quicker turnaround times and enhance customer experiences. It features state of the art cGMP cleanrooms, and GLP Quality Control Laboratories to meet FDA quality regulations.
Joining SCA's existing Little Rock, Arkansas location, this new site allows SCA to combine significant teams and resources to meet customers' needs and exceed expectations. The company employs more than 360 employees with over 140 in Connecticut. As the Windsor facility expands over the next 3 years, SCA plans to add over 200 additional full-time positions.
About SCA Pharmaceuticals
SCA Pharmaceuticals is an FDA 503B outsourcing facility providing the highest quality sterile admixtures and prefilled syringes. Licensed in all 50 states, SCA offers a robust catalogue, as well as outstanding Quality and Customer Service. Since day 1, SCA has performed 100% final product sterility testing with lot specific lab reports for every sterile product produced. SCA additionally performs environmental monitoring and full endotoxin testing on every batch of sterile products, prior to release, fulfilling requirements for Endotoxin (Pyrogen) testing per USP <85> Guidelines and cGMP guidance.
For more information, visit www.scausa.net.
SOURCE SCA Pharmaceuticals